Emily Leproust

Emily Leproust is an American scientist and entrepreneur. She is the CEO and co-founder[1] of Twist Bioscience, a public company working on DNA synthesis. The company harnesses synthetic biology, providing tools to manufacture insulin from yeast, to tackle malaria,[2] produce spider silk at scale[3] or store information on DNA.[4][5] She was awarded the BIO Rosalind Franklin Award in 2020.[6]

Education and career

Leproust earned an M.Sc. in Industrial Chemistry from the Lyon School of Industrial Chemistry[7] in 1995 and a PhD in Organic Chemistry & Nucleic Acids Chemistry from the University of Houston in 2001.[8] She worked for the company Agilent where she was Director of Applications and Chemistry R&D—Genomics before starting the company Twist Bioscience.

Leproust participated in a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.[9]

Publications

  • Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, Brockman W, Fennell T, Giannoukos G, Fisher S, Russ C, Gabriel S. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nature biotechnology. 2009 Feb;27(2):182-9.
  • Kaplan N, Moore IK, Fondufe-Mittendorf Y, Gossett AJ, Tillo D, Field Y, LeProust EM, Hughes TR, Lieb JD, Widom J, Segal E. The DNA-encoded nucleosome organization of a eukaryotic genome. Nature. 2009 Mar;458(7236):362-6.
  • Goldman N, Bertone P, Chen S, Dessimoz C, LeProust EM, Sipos B, Birney E. Towards practical, high-capacity, low-maintenance information storage in synthesized DNA. Nature. 2013 Feb;494(7435):77-80.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.